|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M and Rabe KF: Precision diagnosis
and treatment for advanced non-small-cell lung cancer. N Engl J
Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (Eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmed H and AlSadek DM: Galectin-3 as a
potential target to prevent cancer metastasis. Clin Med Insights
Oncol. 9:113–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cardoso AC, Andrade LN, Bustos SO and
Chammas R: Galectin-3 determines tumor cell adaptive strategies in
stressed tumor microenvironments. Front Oncol. 6:1272016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chung LY, Tang SJ, Wu YC, Sun GH, Liu HY
and Sun KH: Galectin-3 augments tumor initiating property and
tumorigenicity of lung cancer through interaction with β-catenin.
Oncotarget. 6:4936–4952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL: Hypoxia-inducible factors:
Mediators of cancer progression and targets for cancer therapy.
Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeng Y, Danielson KG, Albert TJ, Shapiro
IM and Risbud MV: HIF-1 alpha is a regulator of galectin-3
expression in the intervertebral disc. J Bone Miner Res.
22:1851–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Oliveira JT, Ribeiro C, Barros R, Gomes
C, de Matos AJ, Reis CA, Rutteman GR and Gärtner F: Hypoxia
up-regulates galectin-3 in mammary tumor progression and
metastasis. PLoS One. 10:e01344582015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng J, Lu W, Wang C, Xing Y, Chen X and
Ai Z: Galectin-3 induced by hypoxia promotes cell migration in
thyroid cancer cells. Oncotarget. 8:101475–101488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ikemori RY, Machado CM, Furuzawa KM,
Nonogaki S, Osinaga E, Umezawa K, de Carvalho M, Verinaud L and
Chammas R: Galectin-3 up-regulation in hypoxic and nutrient
deprived microenvironments promotes cell survival. PLoS One.
9:e1115922014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hetmanski JH, Schwartz JM and Caswell PT:
Modelling GTPase dynamics to understand RhoA-driven cancer cell
invasion. Biochem Soc Trans. 44:1695–1700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brew CT, Aronchik I, Kosco K, McCammon J,
Bjeldanes LF and Firestone GL: Indole-3-carbinol inhibits
MDA-MB-231 breast cancer cell motility and induces stress fibers
and focal adhesion formation by activation of Rho kinase activity.
Int J Cancer. 124:2294–2302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao X, Balan V, Tai G and Raz A:
Galectin-3 induces cell migration via a calcium-sensitive
MAPK/ERK1/2 pathway. Oncotarget. 5:2077–2084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Serizawa N, Tian J, Fukada H, Baghy K,
Scott F, Chen X, Kiss Z, Olson K, Hsu D, Liu FT, et al: Galectin 3
regulates HCC cell invasion by RhoA and MLCK activation. Lab
Invest. 95:1145–1156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dumont P, Berton A, Nagy N, Sandras F,
Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C and
Salmon I: Expression of galectin-3 in the tumor immune response in
colon cancer. Lab Invest. 88:896–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gaida MM, Bach ST, Günther F, Baseras B,
Tschaharganeh DF, Welsch T, Felix K, Bergmann F, Hänsch GM and
Wente MN: Expression of galectin-3 in pancreatic ductal
adenocarcinoma. Pathol Oncol Res. 18:299–307. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia-Mata R, Boulter E and Burridge K:
The ‘invisible hand’: Regulation of RHO GTPases by RHOGDIs. Nat Rev
Mol Cell Biol. 12:493–504. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shalom-Feuerstein R, Plowman SJ, Rotblat
B, Ariotti N, Tian T, Hancock JF and Kloog Y: K-ras nanoclustering
is subverted by overexpression of the scaffold protein galectin-3.
Cancer Res. 68:6608–6616. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Song S, Ji B, Ramachandran V, Wang H,
Hafley M, Logsdon C and Bresalier RS: Overexpressed galectin-3 in
pancreatic cancer induces cell proliferation and invasion by
binding Ras and activating Ras signaling. PLoS One. 7:e426992012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimamura T, Sakamoto M, Ino Y, Shimada J,
Kosuge T, Sato Y, Tanaka K, Sekihara H and Hirohashi S:
Clinicopathological significance of galectin-3 expression in ductal
adenocarcinoma of the pancreas. Clin Cancer Res. 8:2570–2575.
2002.PubMed/NCBI
|
|
22
|
Prieto VG, Mourad-Zeidan AA, Melnikova V,
Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed
JA, et al: Galectin-3 expression is associated with tumor
progression and pattern of sun exposure in melanoma. Clin Cancer
Res. 12:6709–6715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Piantelli M, Iacobelli S, Almadori G,
Iezzi M, Tinari N, Natoli C, Cadoni G, Lauriola L and Renalletti
FO: Lack of expression of galectin-3 is associated with a poor
outcome in node-negative patients with laryngeal squamous-cell
carcinoma. J Clin Oncol. 20:3850–3856. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Merseburger AS, Kramer MW, Hennenlotter J,
Serth J, Kruck S, Gracia A, Stenzl A and Kuczyk MA: Loss of
galectin-3 expression correlates with clear cell renal carcinoma
progression and reduced survival. World J Urol. 26:637–642. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mathieu A, Saal I, Vuckovic A, Ransy V,
Vereerstraten P, Kaltner H, Gabius HJ, Kiss R, Decaestecker C,
Salmon I and Remmelink M: Nuclear galectin-3 exprXession is an
independent predictive factor of recurrence for adenocarcinoma and
squamous cell carcinoma of the lung. Mod Pathol. 18:1264–1271.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szöke T, Kayser K, Trojan I, Kayser G,
Furak J, Tiszlavicz L, Baumhäkel JD and Gabius HJ: The role of
microvascularization and growth/adhesion-regulatory lectins in the
prognosis of non-small cell lung cancer in stage II. Eur J
Cardiothorac Surg. 31:783–787. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kosacka M, Piesiak P, Kowal A, Gołecki M
and Jankowska R: Galectin-3 and cyclin D1 expression in non-small
cell lung cancer. J Exp Clin Cancer Res. 30:1012011. View Article : Google Scholar : PubMed/NCBI
|
